Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.

Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP

Findings suggest a potential correlation between motor function improvement and decreased autophagy-related protein levels in patients with spinal muscular atrophy treated with nusinersen.

Nusinersen-Related Improvements in Motor Function Correlate With Reduced Autophagy Markers of Spinal Muscular Atrophy

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.

Sarcopenia Shows Association to Higher Risk of Chemotherapy-Induced Peripheral Neurotoxicity

Videos

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]

Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

, has been with the team since September 2022. Follow her on Twitter 

The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]

Advancing ALS Through Gene Therapies, Early Intervention, and Multidisciplinary Care: Brian Lin, PhD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Seif Elbualy, MD, discusses his role at the Brain and Spine Symposium and shares insights on the future of interventional pain management, evolving techniques, and pharmaceutical innovation.

Overviewing 2025 Baptist Health Brain and Spine Symposium: Exploring New Options in Chronic Pain Management

The director of the Tuberous Sclerosis Program at Cleveland Clinic provided clinical commentary on a novel clustering analysis in TSC, revealing how phenotype-genotype insights can lead to more personalized treatment and surveillance.

NeuroVoices: Ajay Gupta, MD, on Phenotyping Tuberous Sclerosis Complex Into Disease Clusters

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Slideshows

Which vitamins and supplements have shown promise in treating dementia and preventing cognitive decline?

Clinical

9 Natural Supplements for Cognitive Impairment